Nvidia's new Vera CPU is posting competitive server performance against AMD and Intel, while investor Michael Burry warns the stock faces significant downside risk. The chip performance gains matter for healthcare AI infrastructure because clinical deployments increasingly depend on CPU efficiency for real-time inference at the edge and in smaller hospital systems that cannot justify GPU-heavy architectures. Healthcare organizations evaluating Nvidia infrastructure for EHR integration, radiology AI pipelines, or predictive analytics should monitor this competitive pressure, as pricing power and margin sustainability directly affect total cost of ownership for AI-enabled workflows. The divergence between technical performance and market valuation reflects broader uncertainty in the AI hardware landscape that IT leaders must factor into multi-year infrastructure planning.